GSK Likely to Deliver In-Line Q3, RBC Says

12:26 PM EDT, 10/13/2026 (MT Newswires) -- GSK (GSK) is expected to report an in-line Q3, with vaccine headwinds partially offset by strength in HIV and Nucala, RBC said in a Tuesday report. The Q3 results are due Oct. 28. "We are expecting a quiet rest of the year as the focus shifts to the new cost savings plan and pivotal study starts into 2027," the report said. The report said GSK is expected to narrow its guidance to closer to 4% to 5% on the top-line and 7% to 8% on the bottom line. The note also pointed to a likely 1% headwind on the top-line, which is not being factored into latest consensus estimates. "Catalysts remain light through year-end, with the upcoming bepirovirsen PDUFA and some incremental data updates at ESMO," the report said. RBC kept its sector perform rating. Price: 46.44, Change: -0.48, Percent Change: -1.02